EP1517898A1 - Aryl- et heteroarylcarbonylpiperazines et leur utilisation dans le traitement de maladies tumorales benignes et malignes - Google Patents

Aryl- et heteroarylcarbonylpiperazines et leur utilisation dans le traitement de maladies tumorales benignes et malignes

Info

Publication number
EP1517898A1
EP1517898A1 EP03761482A EP03761482A EP1517898A1 EP 1517898 A1 EP1517898 A1 EP 1517898A1 EP 03761482 A EP03761482 A EP 03761482A EP 03761482 A EP03761482 A EP 03761482A EP 1517898 A1 EP1517898 A1 EP 1517898A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
aryl
heteroaryl
heterocyclyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03761482A
Other languages
German (de)
English (en)
Inventor
Peter Emig
Matthias Gerlach
Emmanuel Polymeropoulos
Gilbert MÜLLER
Peter Schmidt
Silke Baasner
Eckhard Günther
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aeterna Zentaris GmbH
Original Assignee
Zentaris AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris AG filed Critical Zentaris AG
Publication of EP1517898A1 publication Critical patent/EP1517898A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • Aryl- and heteroarylcarbonylpiperazines and their use for the treatment of benign and malignant tumor diseases are provided.
  • tumors are a fundamental disease of higher organisms in the plant, animal and human kingdoms.
  • the generally recognized multi-step model of cancer development assumes that the accumulation of several mutations in a single cell changes their proliferation and differentiation behavior in such a way that a malignant state with metastasis is ultimately achieved via benign intermediate stages.
  • the term cancer or tumor hides a clinical picture with more than 200 different individual diseases. Tumor diseases can be benign or malignant.
  • the main tumors are those of the lungs, breast, stomach, cervix, prostate, head and neck, colon and rectum, liver and blood system.
  • the present invention relates to new aryl- and heteroaryl-substituted piperazinylcarbonyls and their homologues, their production and use as medicaments, in particular for the treatment of benign and malignant tumors in humans and mammals.
  • the patents WO2002008194, WO2002008192 and WO2002008190 from the company Zentaris AG describe substituted and unsubstituted acridine, quinoline or pyridinecarbonylpiperazides with anticancerogenic properties.
  • Xanthene derivatives are described in the literature as antispasmodics (US 2742472) and anti-ulcers (US3284449). A tumor effect is neither described nor suggested. Cinnoline derivatives of the above In the literature, substance types have different biological properties, for example as
  • Isoquinoline derivatives and their use as local anesthetics are described by F. Duro et al. in Farmaco, 1981, 36 (6), 400-411.
  • isoquinolines of the above Structure types Use as antipyretics, antiarrhythmics and sedatives (DE2811312, DE2818423). Tumor activity is neither described nor suggested.
  • Isoxazoles and isothiazoles are described in US4001237 and by A. Carenzi et al. Arneistoff Forsch. 1989, 39, 642 as potential antihypertensives. Furthermore, isoxazoles are described as fungicides (J. Heindl et al. Eur. J. of Med. Chem. 1975,10, 591). Isoxazoles are also used as analgesics (DE2065430), muscarinic receptor antagonists (H. g. Striegel et al. European J. of Med. Chem. 1995, 30, 839), with antibacterial properties (A. Pae et al. Biorg. Med Chem. Lett. 1999, 18, 2679) in the literature.
  • R1 fluoren-9-one, isoxazole, cinnoline, isothiazole, isoquinoline, 9H-fluorene, 9H-xanthene and 1 H-pyrazole, where the binding can take place via any and possible ring member of the heteroaryl or aryl radical and the aromatics and heteroaromatics can be substituted one or more times or can be unsubstituted,
  • R2 O, S;
  • R3 represents one or up to 16 substituents selected from the group: H, unsubstituted or substituted alkyl, halogen, COOH, CONH2, where the substituents can be arranged vicinally or geminally on the heterocycle;
  • R4 unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted alkylaryl, unsubstituted or substituted alkylhetaryl;
  • halogen includes the halogen atoms fluorine, chlorine, bromine and iodine.
  • metal in this sense of this invention includes metal ions such as sodium, potassium, lithium, magnesium, calcium, zinc and manganese ions.
  • alkyl includes acyclic saturated or unsaturated hydrocarbon radicals which may be branched or straight-chain and unsubstituted or mono- or polysubstituted may be substituted, having 1 to 20 carbon atoms, ie, Cr 2 o-alkanyls, C 2-20 alkenyls, and C 2 -..
  • 2 o-alkynyl case have alkenyls at least one C-C double bond and alkynyls one C-C triple bond
  • cycloalkyl for the purposes of this invention means cyclic hydrocarbons having 3-12 carbon atoms, which can be saturated or unsaturated, unsubstituted or substituted.
  • the cycloalkyl radical can also be part of a bi- or polycyclic system.
  • heterocyclyl stands for a 3-, 4-, 5-, 6-, 7- or 8-membered cyclic organic radical which contains at least 1, possibly 2, 3, 4 or 5 heteroatoms, the heteroatoms being the same or are different and the cyclic radical is saturated or unsaturated but not aromatic and can be unsubstituted or mono- or polysubstituted.
  • the heterocycle can also be part of a bi- or polycyclic system. Preferred heteroatoms are nitrogen, oxygen and sulfur.
  • heterocyclyl radical is selected from the group containing tetrahydrofuryl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl, it being possible for the bond to the compound of the general formula 1 to be effected via any ring member of the heterocyclyl radical.
  • aryl means aromatic hydrocarbons, including phenyls, naphthyls and anthracenyls.
  • the radicals can also be condensed with further saturated, (partially) unsaturated or aromatic ring systems.
  • Each aryl radical can be unsubstituted or mono- or polysubstituted , wherein the aryl substituents may be the same or different and in any and possible position of the aryl.
  • heteroaryl stands for a 5-, 6- or 7-membered cyclic aromatic radical which contains at least 1, possibly also 2, 3, 4 or 5 heteroatoms, the heteroatoms being the same or different and the heterocycle being unsubstituted or can be substituted one or more times; in the case of substitution on the heterocycle, the heteroaryl substituents can be identical or different and in any and possible position of the heteroaryl his.
  • the heterocycle can also be part of a bi- or polycyclic system. Preferred heteroatoms are nitrogen, oxygen and sulfur.
  • the heteroaryl radical is selected from the group consisting of pyrrolyl, furyl, thienyl, thiazolyl, triazolyl, tetrazolyl, oxazolyl, isothiazolyl, isoxazolyl, pyrazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, triazinyl, benzoliazylyl Contains, indolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, carbazolyl, phenazinyl, phenothiazinyl, purinyl, acridinyl, phenanthrinyl, the binding to the compounds of general formula 1 taking place via any and possible ring member of the heteroaryl radical can.
  • alkyl-cycloalkyl means for the purposes of the present invention that alkyl and cycloalkyl, heterocyclyl, aryl and heteroaryl have the meanings defined above and that Cycloalkyl, heterocyclyl, aryl or heteroaryl radical is bonded via a C1-8 alkyl group to the compound of general formula 1.
  • alkyl In connection with “alkyl”, “alkenyl” and “alkynyl”, the term substituted in the sense of this invention means the substitution of a hydrogen radical by F, Cl, Br, I, CN, NH 2 , NH-alkyl, NH-cycloalkyl, NH-aryl, NH-heteroaryl, NH-alkyl-aryl, NH-alkyl-heteroaryl, NH-heterocyclyl, NH-alkyl-OH, N (alkyl) 2 , N (alkyl-aryl) 2 , N (alkyl-heteroaryl) 2 , N (heterocyclyl) 2 !
  • one or more substituted means one or more, for example two, three or four times, substitution of one or more Hydrogen atoms of the ring system by F, Cl, Br, I, CN, NH 2 , NH-alkyl, NH-aryl, NH-heteroaryl, NH-alkyl-aryl, NH-alkyl-heteroaryl, NH-heterocyclyl, NH-alkyl-OH , N (alkyl) 2 , NC (0) alkyl, N (alkyl aryl) 2 , N (alkyl heteroaryl) 2 , N (heterocyclyl) 2 , N (alkyl OH) 2 , NO, NO 2 , SH, S-alkyl, S-aryl, S-heteroaryl, S-alkyl-aryl, S-alkyl-aryl, S-al
  • the compounds of general formula 1 according to the invention have at least one asymmetry center, they can be present in the form of their racemates, in the form of the pure enantiomers and / or diastereomers or in the form of mixtures of these enantiomers and / or diastereomers.
  • the mixtures can be present in any mixing ratio of the stereoisomers.
  • the compounds of the invention may be in the form of the tautomers.
  • the compounds of general formula 1 according to the invention which have one or more centers of chirality and which occur as racemates can be separated into their optical isomers, ie enantiomers or diastereomers, by methods known per se.
  • the separation can be carried out by column separation on chiral phases or by recrystallization from an optically active solvent or using an optically active acid or base or by derivatization with an optically active reagent, such as, for example, an optically active alcohol, and subsequent elimination of the rest.
  • the compounds of general formula 1 according to the invention if they have a sufficiently basic group, such as a secondary or tertiary amine, can be converted into salts with inorganic and organic acids.
  • the pharmaceutically acceptable salts of the compounds according to the invention are preferably of the general structure 1 with hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, p-toluenesulfonic acid, carbonic acid, formic acid, acetic acid, sulfoacetic acid, trifluoroacetic acid, oxalic acid, malonic acid, maleic acid, succinic acid, tartaric acid, tartaric acid , Malic acid, embonic acid, mandelic acid, fumaric acid, lactic acid, Citric acid, taurocholic acid, glutamic acid or aspartic acid are formed.
  • the salts formed include hydrochlorides, hydrobromides, sulfates, phosphates, methanesulfonates, tosylates, carbonates, bicarbonates, formates, acetates, sulfoacetates, triflates, oxalates, malonates, maleates, succinates, tartrates, malates, embonates, mandelates, fumarates , Lactates, citrates and glutaminates.
  • the stoichiometry of the salts formed of the compounds according to the invention can be integer or non-integer multiples of one.
  • the compounds of general formula 1 according to the invention if they contain a sufficiently acidic group, such as the carboxy group, sulfonic acid, phosphoric acid or a phenolic group, can be converted into their physiologically tolerable salts with inorganic and organic bases.
  • suitable inorganic bases are sodium hydroxide, potassium hydroxide, calcium hydroxide, and organic bases are ethanolamine, diethanolamine, triethanolamine, cyclohexylamine, dibenzylethylene diamine and lysine.
  • the stoichiometry of the salts formed of the compounds according to the invention can be integer or non-integer multiples of one.
  • Solvates and in particular hydrates of the compounds according to the invention which, for. B. can be obtained by crystallization from a solvent or from aqueous solution.
  • One, two, three or any number of solvate or water molecules can combine with the compounds according to the invention to form solvates and hydrates.
  • the compounds of general formula 1 according to the invention can exist in various polymorphic forms, and certain modifications can be metastable.
  • the compounds according to the invention are provided according to the general formula 1, characterized in that R 1, R 2 , R 3 , n and m have the meanings given above and R represents phenyl which is unsubstituted or with one to five equal to or various (CrC 6 ) alkoxy groups is substituted, and adjacent oxygen atoms can also be linked by (CC 2 ) alkylene groups.
  • compounds according to general formula 1 are provided, characterized in that R, R 1, R 2 , R 3 , n and m have the meanings given above and R is 3,5-dimethoxyphenyl.
  • compounds according to general formula 1 are provided, characterized in that R 1, R 2 , R 3 , n and m have the meanings given above and R 4 is 3-methoxyphenyl.
  • a process for the preparation of the compounds according to the invention is claimed, which is characterized in that a carboxylic acid derivative of the general formula 2, in which R 1 and R 2 have the meanings given above and Y for a leaving group such as halogen, hydroxy , (CrCe) -alkoxy preferably methoxy and ethoxy, -O-tosyl, -O-mesyl, tetrazolyl or imidazolyl,
  • R1 aryl, heteroaryl
  • the starting compounds 2 and 3 are either commercially available or can be prepared by processes known per se.
  • the starting materials 2 and 3 represent valuable intermediates for the preparation of the compounds of formula 1 according to the invention.
  • reaction parameters to be used such as reaction temperature and duration, are known to the person skilled in the art on the basis of his expert knowledge.
  • the compounds of general formula 1 according to the invention are suitable as active ingredients in medicaments, in particular as anti-tumor agents, for the treatment of humans and mammals.
  • Mammals can be pets such as horses, cows, dogs, cats, rabbits, sheep and the like.
  • the medicinal effect of the compounds according to the invention can be based, for example, on an interaction with the tubulin system by inhibiting tubulin polymerization.
  • other known and unknown mechanisms of action to combat tumor cells are also conceivable.
  • a method for combating tumors in humans and in mammals which is characterized in that at least one compound according to the invention according to general formula 1 is administered to humans or a mammal in an amount effective for tumor treatment ,
  • the therapeutically effective dose of the respective compound according to the invention to be administered for the treatment is directed inter alia. according to the type and stage of the tumor, the age and sex of the patient, the type of administration and the duration of treatment.
  • the pharmaceuticals according to the invention can be administered as liquid, semi-solid and solid pharmaceutical forms.
  • the pharmaceutical forms optionally contain auxiliaries, such as, inter alia, solvents, solution accelerators, solubilizers, emulsifiers, wetting agents, anti-foaming agents, gel formers, thickeners, film formers, binders, buffers, salt formers, drying agents, flow regulators, fillers, preservatives , Antioxidants, dyes, mold release agents, lubricants, disintegrants, taste and smell corrections.
  • auxiliaries such as, inter alia, solvents, solution accelerators, solubilizers, emulsifiers, wetting agents, anti-foaming agents, gel formers, thickeners, film formers, binders, buffers, salt formers, drying agents, flow regulators, fillers, preservatives , Antioxidants, dyes, mold release agents, lubricants, disintegrants, taste and smell corrections.
  • auxiliaries such as, inter alia, solvents, solution accelerators, solubilizers, emulsifiers
  • the medicaments according to the invention can be applied to the skin in a suitable dosage form, epicutaneously as a solution, suspension, emulsion, foam, ointment, paste or plaster; over the oral and tongue mucosa, buccal, lingual or sublingually as tablets, lozenges, dragees, linctus or gargle water; via the gastric and intestinal mucosa, enterally as tablets, coated tablets, capsules, solutions, suspensions or emulsions; via the rectal mucosa, rectally as a suppository, rectal capsule or ointment; through the nasal mucosa, nasally as drops, ointments or spray; via the bronchial and alveolar epithelium, pulmonary or by inhalation as aerosol or inhalation; via the conjunctiva, conjunctival as eye drops, eye ointment, eye tablets, lamellae or eyewash; via the mucous membranes of the genital organs, intra
  • the compounds of general structure 1 according to the invention can be extended with regard to practical therapeutic requirements by means of suitable measures in their drug action. This goal can be achieved chemically and / or galenically. Examples of achieving an extension of activity are the use of implants, liposomes, slow-release forms, nanoparticle suspensions and so-called prodrugs of the compounds according to the invention, the formation of sparingly soluble salts and complexes or the use of crystal suspensions.
  • the compounds of general structure 1 according to the invention can be used as a single substance or in combination with other cytotoxic substances, e.g. Cisplatin, carboplatin, doxorubicin, ifosfamide, cyclophosphamide, 5-FU, methotrexate or in combination with immunomodulators or antibodies and in particular in combination with signal transduction inhibitors, such as e.g. Herceptin, Glivec or Iressa can be used.
  • cytotoxic substances e.g. Cisplatin, carboplatin, doxorubicin, ifosfamide, cyclophosphamide, 5-FU, methotrexate or in combination with immunomodulators or antibodies and in particular in combination with signal transduction inhibitors, such as e.g. Herceptin, Glivec or Iressa can be used.
  • Drugs which contain at least one compound from the following group of the compounds according to the invention are particularly preferred: 4- [4- (3,5-Dimethoxyphenyl) piperazin-1-carbonyl] -fluoren-9-one (1) 4- [4- (6-methyl-pyridin-2-yl) piperazin-1 -carbonyl] -fluoren-9-one (2) 4- [4- (3-hydroxyphenyl) piperazin-1-carbonyl] -fluoren-9-one (3) [4- (3,5-dimethoxy- phenyl) piperazin-1-yl] - (5-methyl-3-phenyl-isoxazol-4-yl) - methanone (4)
  • Example 3 (implementation according to scheme 1, variant 2):
  • the most preferred compounds of the present invention are substances of general formula 1 in the form of their bases or their pharmaceutically acceptable salts, which are selected from the following group:
  • the substances according to the invention were tested for their anti-proliferative activity in a proliferation test on established tumor cell lines.
  • the test used determines the cellular dehydrogenase activity and enables a determination of the cell vitality and indirectly the cell number.
  • the cell lines used are the human cervical carcinoma cell line KB / HeLa (ATCC CCL17), the ovarian adenocarcinoma cell line SKOV-3 (ATCC HTB77), the human glioblastoma cell line SF-268 (NCI 503138) and the lung carcinoma cell line. H460 (NCI 503473).
  • an RKOp27 cell system was used to investigate the cell cycle-specific effect of the substance (M. Schmidt et al.
  • RKO is a humane one Colon carcinoma line in which the cell cycle inhibitor p27 k ⁇ p1 can be induced by means of the Ecdyson expression system and brought to a cell cycle arrest specifically in G2.
  • a non-specific substance inhibits proliferation regardless of whether the RKO cell is locked in G1 or G2 or not.
  • cell cycle-specific substances such as tubulin inhibitors are only cytotoxic if cells are not locked and the cell cycle is followed.
  • Table 1 shows the cytotoxic or growth-inhibiting activities of the described compound with / without expression of p27 k ⁇ p1 .
  • the tested compounds showed no cytotoxic activities in the induced state of p27 k ⁇ p1 .
  • the results show a very potent inhibition of the proliferation of selected tumor cell lines by the compounds according to the invention.
  • the adherent growing tumor cell lines KB / HeLa, SKOV-3, SF-268 and NCI-H460 were cultivated under standard conditions in a gas incubator at 37 ° C, 5% C0 2 and 95% humidity.
  • the cells are detached with trypsin / EDTA and pelleted by centrifugation.
  • the cell pellet is then resuspended in the respective culture medium in the appropriate cell number and converted into a 96-well microtiter plate.
  • the plates are then cultivated overnight in the fumigation incubator.
  • the test substances are prepared as 1 mg / ml stock solutions in DMSO and diluted with culture medium in the appropriate concentrations on test day 2.
  • the assay is carried out in 96-well plates. By inducible expression of p27 k ⁇ p1 , the cells are completely arrested for growth, but do not die. By comparing the effectiveness on induced and non-induced cells, conclusions can be drawn about the mechanism of action (cell cycle specificity) of the therapeutic agents. Uninduced cells are sown in approximately three times the number of cells, since there is no division during the assay compared to uninduced cells (20,000 cells / well induced, 6,250 cells / well not induced). The controls are untreated cells (+/- induction). Induction is carried out with 3 ⁇ M M steron A. On the 1st day, the cells are exposed (+/- Muristeron A) and incubated for 24 hours at 37 ° C. On day 2, the test substance is added (control DMSO) and incubated for a further 45 h at 37 ° C. before a standard XTT assay is carried out.
  • Lyophylized bovine tubulin (cytoskeleton, ML 113 tubulin 30% MAPs, TL238 tubulin MAP free) is used in a concentration of 2mg / ml (ML113 in 80mM PIPES, 0.5mM EGTA, 2mM MgCl 2 , pH6.9, 1mM GTP). or 5mg / ml (TL238 in 80mM PIPES, 1mM EGTA, 0.5mM MgCl 2 , 20% (v: v) glycerol pH6.9, 1mM GTP).
  • test substances are diluted in 10% DMSO (v: v) and 5 ⁇ l of the dilutions are transferred to a 96-well microtiter plate (Nunc, half area plate).
  • a 96-well microtiter plate (Nunc, half area plate).
  • the polymerization at 340 nm is determined in a Spectramax 190 microtiter plate reader (molecular devices) using a kinetics program at 30 second intervals over a period of 20 minutes.
  • the resulting area under curve values are used to calculate the inhibition in relation to the untreated control and in the form of a concentration-effect curve applied semi-logarithmically.
  • the EC 50 is calculated using a regression analysis from the concentration-effect curve using the Graphpad Prism program.
  • (1) is triturated with (3). This trituration is added to the mixture of (2) and (4) with intensive mixing. This powder mixture is filled into size 3 hard gelatin capsules on a capsule filling machine.

Abstract

L'invention concerne de nouveaux aryl- et hétéroarylcarboxamides de formule générale (I), leur production et leur utilisation comme médicaments, en particulier dans le traitement de tumeurs.
EP03761482A 2002-06-29 2003-06-20 Aryl- et heteroarylcarbonylpiperazines et leur utilisation dans le traitement de maladies tumorales benignes et malignes Withdrawn EP1517898A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39302702P 2002-06-29 2002-06-29
US393027P 2002-06-29
PCT/EP2003/006555 WO2004002965A1 (fr) 2002-06-29 2003-06-20 Aryl- et heteroarylcarbonylpiperazines et leur utilisation dans le traitement de maladies tumorales benignes et malignes

Publications (1)

Publication Number Publication Date
EP1517898A1 true EP1517898A1 (fr) 2005-03-30

Family

ID=30000964

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03761482A Withdrawn EP1517898A1 (fr) 2002-06-29 2003-06-20 Aryl- et heteroarylcarbonylpiperazines et leur utilisation dans le traitement de maladies tumorales benignes et malignes

Country Status (18)

Country Link
US (1) US20040097734A1 (fr)
EP (1) EP1517898A1 (fr)
JP (1) JP2005538968A (fr)
CN (1) CN100509790C (fr)
AR (1) AR040315A1 (fr)
AU (1) AU2003246571B2 (fr)
BR (1) BR0312294A (fr)
CA (1) CA2433983A1 (fr)
HK (1) HK1080840A1 (fr)
HR (1) HRP20050092A2 (fr)
MX (1) MXPA04012959A (fr)
NO (1) NO20050428L (fr)
NZ (1) NZ537916A (fr)
PL (1) PL375527A1 (fr)
RU (1) RU2335496C2 (fr)
UA (1) UA79286C2 (fr)
WO (1) WO2004002965A1 (fr)
ZA (1) ZA200409610B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004218260A1 (en) * 2003-01-28 2004-09-16 Aventis Pharma S.A. N-aryl heteroaromatic products, compositions containing same and use thereof
JP2006525355A (ja) * 2003-05-01 2006-11-09 アボット・ラボラトリーズ ナトリウムチャンネルモジュレーターとしてのピラゾール−アミドおよびスルホンアミド
FR2855825B1 (fr) * 2003-06-04 2008-08-22 Aventis Pharma Sa Produits aryl-heteroaromatiques, compositions les contenant et utilisation
AR044586A1 (es) * 2003-06-04 2005-09-21 Aventis Pharma Sa Productos aril - heteroaromaticos, composiciones que los contienen y su utilizacion
EP1645556A1 (fr) * 2004-10-07 2006-04-12 Boehringer Ingelheim International GmbH Derives d'arylpiperazine-benzoylamide utiles comme agents pharmaceutiques
WO2007014198A1 (fr) 2005-07-25 2007-02-01 Synta Pharmaceuticals Corp. Composes utiles pour le traitement des maladies proliferatives
AU2007275301A1 (en) * 2006-07-20 2008-01-24 Amgen Inc. Substituted azole aromatic heterocycles as inhibitors of 11-beta-HSD-1
KR100932093B1 (ko) 2006-09-27 2009-12-16 주식회사종근당 미세소관 형성 저해제로서 유용한 벤조페논 유도체
MX2010001742A (es) * 2007-08-13 2010-03-10 Hoffmann La Roche Nuevos derivados de piperazina-amida.
CN101597278B (zh) 2008-06-04 2013-04-17 中国中化股份有限公司 酰胺类化合物及其制备与应用
US9212177B2 (en) * 2009-08-05 2015-12-15 Versitech Limited Antiviral compounds and methods of making and using thereof
US20120142701A1 (en) * 2010-05-28 2012-06-07 The University Of Hong Kong Compounds and methods for the treatment of proliferative diseases
KR101369584B1 (ko) 2011-04-19 2014-03-06 일양약품주식회사 페닐-이속사졸 유도체 및 그의 제조방법
CA3034211A1 (fr) * 2016-08-18 2018-02-22 Vidac Pharma Ltd. Derives de piperazine, compositions pharmaceutiques et leurs procedes d'utilisation
US10682346B2 (en) 2016-11-07 2020-06-16 Vidac Pharma Ltd. Use of hexokinase 2/mitochondria-detaching compounds for activating immune responses
US11266639B2 (en) 2016-11-07 2022-03-08 Vidac Pharma Ltd. Use of hexokinase 2/mitochondria-detaching compounds for treating hexokinase-2 (HK2)-expressing cancers
RU2700576C1 (ru) * 2019-05-07 2019-09-18 Федеральное государственное бюджетное научное учреждение "Институт экспериментальной медицины" (ФГБНУ "ИЭМ") Анксиолитическое средство
CN111303132B (zh) * 2020-03-19 2023-05-23 辽宁孚音生物科技有限公司 一种抗癌化合物及其制备方法和应用
BR112023002497A2 (pt) * 2020-08-12 2023-05-02 Spruce Biosciences Inc Métodos e composições para tratamento da síndrome dos ovários policísticos

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1620016C3 (de) * 1966-07-02 1979-08-30 Merck Patent Gmbh, 6100 Darmstadt 3-{Piperazinoalkyl)-pyrazole und Verfahren zu ihrer Herstellung
US3468882A (en) * 1966-10-07 1969-09-23 Sterling Drug Inc Phenylhydrazone derivatives as intermediates for preparing indoles
BE791501A (fr) * 1971-11-19 1973-05-17 Albert Ag Chem Werke Diamines cycliques n,n'-disubstituees et leur procede de preparation
DK65177A (da) * 1976-02-18 1977-08-19 Bristol Myers Co Azolamider
JPS6477A (en) * 1987-03-24 1989-01-05 Takeda Chem Ind Ltd 1,4-disubstituted piperazine compound
EP0385043A1 (fr) * 1989-02-28 1990-09-05 Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. (Faes) Dérivés de pipérazinessubstituées en 4
JPH03218371A (ja) * 1989-08-02 1991-09-25 Takeda Chem Ind Ltd ピラゾール誘導体
US5563142A (en) * 1989-12-28 1996-10-08 The Upjohn Company Diaromatic substituted compounds as anti-HIV-1 agents
US5416087A (en) * 1990-10-10 1995-05-16 Wong; Jesse K. Bis-benzo, cyclohepta piperidylidene, piperidine and piperazine compounds, compositions and methods of use
DE4219247A1 (de) * 1992-06-12 1993-12-16 Bayer Ag Verwendung von 3-arylsubstituierten 5-Alkyl-isoxazol-4-carbonsäurederivaten zur Bekämpfung von Endoparasiten, neue 3-arylsubstituierte 5-Alkyl-isoxazol-4-carbonsäurederivate und Verfahren zu ihrer Herstellung
WO1994024095A1 (fr) * 1993-04-16 1994-10-27 Abbott Laboratories Agents immunosuppresseurs
US6262059B1 (en) * 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
AU713171B2 (en) * 1996-06-29 1999-11-25 Samjin Pharmaceutical Co., Ltd. Piperazine derivatives and process for the preparation thereof
ES2125206B1 (es) * 1997-07-21 1999-11-16 Esteve Labor Dr Derivados de acil-piperazinil-pirimidinas, su preparacion y su aplicacion como medicamentos.
US6166203A (en) * 1998-02-26 2000-12-26 Neurogen Corporation Heterocyclic amino substituted heteroaryl fused pyridines; GABA brain receptor ligands
CN1230421C (zh) * 1999-02-10 2005-12-07 三菱制药株式会社 酰胺化合物及其药物用途
CA2362495A1 (fr) * 1999-03-03 2000-09-08 Theresa M. Williams Inhibiteurs de prenyl-proteine transferases
TR200201413T2 (tr) * 1999-09-17 2003-02-21 Millennium Pharmaceuticals, Inc. Faktör Xa' nın inhibitörleri.
DE10035908A1 (de) * 2000-07-21 2002-03-07 Asta Medica Ag Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel
DE10035927A1 (de) * 2000-07-21 2002-03-07 Asta Medica Ag Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel
DE10035928A1 (de) * 2000-07-21 2002-03-07 Asta Medica Ag Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel
WO2002020436A2 (fr) * 2000-09-05 2002-03-14 Neogenesis Pharmaceuticals, Inc. Procedes de formation de bibliotheques combinatoires combinant la formation de liaisons amide et l'ouverture d'epoxyde
US20020072081A1 (en) * 2000-09-06 2002-06-13 Wai-Si Eng Geranylgeranyl transferase inhibitor screening assay
FR2815032B1 (fr) * 2000-10-10 2003-08-08 Pf Medicament Nouveaux derives d'aminophenyle piperazine ou d'amino phenyle piperide inhibiteurs de proteines prenyl transferase ainsi que leurs preparations
DE10102053A1 (de) * 2001-01-17 2002-07-18 Merck Patent Gmbh Piperazinylcarbonylchinoline und -isochinoline
ES2180456B1 (es) * 2001-07-20 2004-05-01 Laboratorios S.A.L.V.A.T., S.A. Isoxazoles sustituidos y su utilizacion como antibioticos.
JP4440642B2 (ja) * 2001-12-20 2010-03-24 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ピリミジンＡ２ｂ選択的アンタゴニスト化合物、それらの合成、及び使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004002965A1 *

Also Published As

Publication number Publication date
NO20050428L (no) 2005-01-25
CA2433983A1 (fr) 2003-12-29
NZ537916A (en) 2005-11-25
WO2004002965A1 (fr) 2004-01-08
HRP20050092A2 (en) 2005-02-28
JP2005538968A (ja) 2005-12-22
AU2003246571A1 (en) 2004-01-19
CN100509790C (zh) 2009-07-08
CN1665792A (zh) 2005-09-07
US20040097734A1 (en) 2004-05-20
AU2003246571B2 (en) 2008-06-26
MXPA04012959A (es) 2005-05-16
RU2005102478A (ru) 2005-07-20
PL375527A1 (en) 2005-11-28
AR040315A1 (es) 2005-03-23
HK1080840A1 (en) 2006-05-04
UA79286C2 (en) 2007-06-11
BR0312294A (pt) 2005-04-12
RU2335496C2 (ru) 2008-10-10
ZA200409610B (en) 2005-05-25

Similar Documents

Publication Publication Date Title
WO2004002965A1 (fr) Aryl- et heteroarylcarbonylpiperazines et leur utilisation dans le traitement de maladies tumorales benignes et malignes
EP1280798B1 (fr) Heterocycles bicycliques, medicaments contenant ces composes, leur utilisation et leur procede de production
EP3386979B1 (fr) Dérivés 2-phényl-3-(pipérazinométhyl)imidazo[1,2-a]pyridine en tant que bloquers de canaux task-1 et task-2 pour le traitement de troubles respiratoires du sommeil
EP1315718B1 (fr) Heterocycles bicycliques, medicaments contenant lesdits composes, leur utilisation et procedes permettant de les produire
EP1636228B1 (fr) Nouvelles pyridopyrazines et leur utilisation en tant que modulateurs de kinases
EP1731511A1 (fr) Hetrrocycles bicycliques, medicaments contenant lesdits composés, leur utilisation et procédés permettant de les préparer
DE10042062A1 (de) Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Hertellung
EP1628976A1 (fr) Nouvelles pyridopyrazines et leur utilisation en tant qu'inhibiteurs de kinases
DE102006050515A1 (de) Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung
DE10042060A1 (de) Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10042061A1 (de) Bicyclische Heterocyclen,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
EP2241557A1 (fr) Dérivés de chinoxaline et leur utilisation pour le traitement de tumeurs bénignes et malignes
WO2005007643A1 (fr) Nouveaux derives d'acridine et leur utilisation comme medicaments
EP1611126B1 (fr) Chromenonindole
DE10042064A1 (de) Chinazoline, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO2008015265A1 (fr) Dérivés de l'anthracène et leur utilisation pour le traitement d'affections tumorales bénignes et malignes
WO2004007470A1 (fr) Nouveaux derives d'anthracene et leur utilisation comme medicaments
DE602004009097T2 (de) 1.3.4-triaza-phenalen- und 1,3,4,6-tetraazaphenalen-derivate
DE60203740T2 (de) Luminacine analoge und deren verwendung
EP1897864A1 (fr) Derivés anthracènes et l'utilisation en traitement de cancer
EP1651600A2 (fr) Nouveaux amides d'acide indolyl-3-glyoxylique n-substitues, leur utilisation comme medicaments et procede pour leur production
DE19618970A1 (de) Neue Thiazolopyridine
DE10232525A1 (de) Neue Anthracen-Derivate und deren Verwendung als Arzneimittel
EP1484329A1 (fr) Dérivés d'indole déstinés à l'induction d'apoptose
KR20050016946A (ko) 아릴카보닐피페라진과 헤테로아릴카보닐피페라진 및 양성및 악성 종양 질환을 치료하기 위한 이들의 용도

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041125

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GUENTHER, ECKHARD

Inventor name: BAASNER, SILKE

Inventor name: SCHMIDT, PETER

Inventor name: MUELLER, GILBERT

Inventor name: POLYMEROPOULOS, EMMANUEL

Inventor name: GERLACH, MATTHIAS

Inventor name: EMIG, PETER

RAX Requested extension states of the european patent have changed

Extension state: MK

Payment date: 20041125

Extension state: LV

Payment date: 20041125

Extension state: LT

Payment date: 20041125

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ZENTARIS GMBH

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AETERNA ZENTARIS GMBH

17Q First examination report despatched

Effective date: 20090217

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20101008